Table 2 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer

Table 2 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer

<p>Treatment-emergent adverse events by Common Terminology Criteria for Adverse Events v5.0, grade 1–4 occurring in at least 10% of patients and all grade 5, at the patient level.</p>

Saved in:
Bibliographic Details
Main Author: Robert W. Lentz (17013559) (author)
Other Authors: Julie Lang (20519739) (author), Todd M. Pitts (17013577) (author), Patrick Blatchford (22652193) (author), Junxiao Hu (16157686) (author), Kimberly R. Jordan (15049505) (author), Adrie Van Bokhoven (22652196) (author), Stacey M. Bagby (17013565) (author), Adrian T.A. Dominguez (19529151) (author), Cameron A. Binns (22652199) (author), Hannah R. Robinson (19529136) (author), Nicole Balmaceda (22652202) (author), Emily Baiyee (22652205) (author), Alexis D. Leal (17013562) (author), Sunnie S. Kim (19529139) (author), S. Lindsey Davis (14032353) (author), Christopher H. Lieu (15018279) (author), Raymond C. Wadlow (22652208) (author), Kristen Spencer (22652211) (author), Aaron J. Scott (15133937) (author), Patrick M. Boland (15037142) (author), Howard S. Hochster (15022088) (author), Wells A. Messersmith (17013568) (author)
Published: 2025
Subjects:
Cancer
Immuno-oncology
Clinical Research and Trials
Clinical Trial Results
Phase II clinical trials
Checkpoint Blockade
Colorectal Cancer
Combination Immunotherapy
Gastrointestinal Cancers
Immunotherapy
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items